Recently viewed

All Categories

Baraclude Baraclude is an antiviral agent for the treatment of chronic hepatitis B virus (HBV) infection characterized by a dynamic multiplication of the virus as well as steadily elevated concentrations of the liver enzymes in the blood and active liver inflammation and/or fibrosis. The medicine works by decreasing the amount of hepatitis B virus in the body and is helpful in patients aged 2 years and above with either compensated or decompensated liver disease.
Quantity per bottle Pack Price

Baraclude

1mg; 30 pills bottle

Quantity

1 bottle

per bottle

USD 186.89

Pack Price

USD 186.89
Add to Cart

Baraclude

1mg; 30 pills bottle

Quantity

2 bottles

per bottle

USD 165.44

Pack Price

USD 330.88
Add to Cart

Baraclude

1mg; 30 pills bottle

Quantity

3 bottles

per bottle

USD 160.24

Pack Price

USD 480.72
Add to Cart

Baraclude

1mg; 30 pills bottle

Quantity

4 bottles

per bottle

USD 152.51

Pack Price

USD 610.05
Add to Cart

- USD 15.00

Registered Mail - 14-21 business days, price - USD 15.00, no signature is required on delivery. (14-21 business days)

- USD 25.00

EMS - 5-9 business days, price - USD 25.00, signature is required on delivery. (5-9 business days)

General Info

Description

Baraclude is a medication with potent activity against chronic hepatitis B virus (HBV). The active ingredient present in the medication is Entecavir, an HBV nucleoside analog reverse transcriptase inhibitor (NRTI), utilized for the treatment of chronic hepatitis B virus infection in relations to an active viral replication and constantly elevated levels of liver enzymes in the blood. The medicine suppresses viral copying in hepatitis B infected patients with either compensated or decompensated liver disease preventing further spreading of the virus through the body.

Anti-hepatitis B therapy with Baraclude helps to reduce inflammation of the liver and lower the chance for disease-related complications like fibrosis. It has also shown its effectiveness in patients who have never used antiviral medicines before (nucleoside-naive) and those immune to the treatment with lamivudine-containing drugs (lamivudine-refractory).

Despite the drug's positive profile in HBV-infected patients therapy, it does not have the ability to kill the virus completely, hence, there is still a chance for passing it on to the others. To prevent the spread of HBV, which can be done through blood contamination or sexual contact, one should avoid sharing needles and unprotected intercourse. Baraclude may also be used to treat people with both HBV and HIV if only such therapy is supported by an effective anti-HIV drug.

Indications

Treatment of chronic hepatitis B virus (HBV) infection in patients with:

  • compensated liver disease (liver is damaged but still functions in a proper way);
  • decompensated liver disease (liver is damaged and does not function properly).
MOA (mechanism of action)

Entecavir present in the anti-hepatitis B formulation is a representative of a nucleoside reverse transcriptase inhibitors (NRTIs) drug class. It is a guanosine nucleoside analog that works by suppressing reverse transcriptase through phosphorylation into its active triphosphate form. Having transformed into triphosphate metabolite, Entecavir interacts with the natural substrate, deoxyguanosine triphosphate, competing for viral reverse transcriptase (RT). The medicine is further incorporated into the viral DNA, where it shows its virus-inhibiting activity by acting in three main directions, i.e., base priming prevention, RNA (negative strand) reverse transcription, and HBV (positive strand) synthesis. The active substance is also beneficial in nucleoside-naive and lamivudine-refractory patients with HBeAg-positive and HBeAg-negative HBV infection.

Dosage

Baraclude is indicated for the oral administration on a daily basis. The medication should be taken on an empty stomach at least 2 hours before or 2 hours after meal intake. Patients who cannot swallow the tablets may be advised to take the medicine in a liquid dosage form (an oral solution).

Maximum dose: 1 mg per day.

Baraclude should be used for as long as recommended by a doctor and not be stopped abruptly as this may worsen the disease. Patients who have discontinued the treatment should be under thorough medical supervision for a few months. Their hepatic function should be closely monitored with regular blood tests taking in order to avoid the hepatitis B severe acute exacerbations.

Dosage adjustment is advised in patients with renal insufficiency (creatinine clearance less than 50 ml/min), including those undergoing hemodialysis or CAPD (a type of peritoneal dialysis).

Missed dose

If you miss a dose of Baraclude you should take it as soon as you remember. If it is the time for the next dose you should continue your regular dosing schedule. Do not take a double dose to make up for a missed one.

Overdose

If an overdose occurs and you are feeling unwell, you should seek emergency medical attention or contact your healthcare provider immediately.

Storage

Store at room temperature below 30°C (86°F) away from excess moisture and heat. Throw away any unused medicine after the expiration date. Keep out of the reach of children.

Safety Information

Side effects

The most common side effects associated with Baraclude are:

  • hepatomegaly (liver enlargement) and/or steatosis (fat in the liver)
  • elevated liver enzymes
  • lactic acidosis (buildup of acid in the blood)
  • skin rash and/or hives
  • headache
  • trouble sleeping
  • tiredness
  • dizziness
  • muscle pain and cramps
  • abdominal pain
  • diarrhea
  • nausea
  • vomiting
  • upset stomach
  • palpitations
  • trouble breathing
  • cough
  • wheezing

Side effect occurrence does not only depend on medication you are taking but also on your overall health and other factors.

Contraindications

Baraclude is not for use in people with a known allergy to Entecavir or any of the other drug components.

Do not give the medication to patients with a history of serious kidney problems.

Do not take the medicine if you have or have had pancreatitis (inflammation of the pancreas).

Do not use the drug if you one of the following hereditary problems: galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption.

Do not use the medicine in patients co-infected with HIV and who are not on highly effective antiviral therapy for HIV due to the risk of HIV NRTIs resistance development.

Do not co-administrate Baraclude with the immune system-weakening medicines (e.g., steroids or cancer drugs), aminoglycoside antibiotics (such as amikacin, gentamicin, neomycin, kanamycin, paromomycin, streptomycin, and tobramycin), antifungals (like amphotericin B), medications to prevent a transplanted organ rejection (e.g., cyclosporine, sirolimus or tacrolimus), other antibiotics (like capreomycin, rifampin, vancomycin), antimicrobial medications (such as pentamidine).

Do not take Baraclude tablets if you are pregnant or breastfeeding without talking to your doctor first.

Do not give this medicine to patients below 2 years of age without a doctor’s recommendation.

F.A.Q.

Q: What does Baraclude treat?

A: The medication is an antiviral agent indicated for the treatment of chronic hepatitis B virus (HBV) infection with the evidence of virus multiplication and constantly high levels of hepatic enzymes in the blood and active liver inflammation and/or fibrosis. The medicine helps to reduce the amount of HBV in the body, alleviate active liver inflammation and/or fibrosis.

Q: How the medicine is to be administered?

A: Baraclude is to be used on a daily basis via the oral administration route only. The tablets must be taken on an empty stomach(at least 2 hours before or 2 hours after a meal). For those patients who are unable to swallow the medicine, Baraclude may be advised in the form of an oral solution.

Q: Can I use Baraclude during pregnancy or when breastfeeding?

A: The medication is not recommended for use in pregnant or breastfeeding women unless strictly indicated and the potential benefits are higher than the risks involved.

Testimonials

Leave Your Comment